Analysts’ recommendations and target price
Wall Street analysts expect a potential upside of 26.25% for Sage Therapeutics (SAGE) based on the company’s closing price on March 27. Analysts revised the company’s target price downward twice, from $201.06 in January to $200.56 in February and then to $200.44 in March.
The current consensus analyst recommendation for the stock is a “buy.”
Of the 17 analysts covering Sage Therapeutics, eight are recommending “strong buys,” eight are recommending “buys,” and one is recommending a “sell.” The highest and lowest target price estimates for the company are $249 and $90, respectively.
On March 27, Sage Therapeutics closed at $158.76, 2.99% lower than its previous closing price, 98.75% higher than its 52-week low of $79.88, and 15.92% lower than its 52-week high of $188.82.
Based on its closing price on March 27, Sage Therapeutics has reported returns of 4.13% in the last week, 3.93% in the last month, and 89.97% in the last quarter. The company has reported returns of -8.73% in the last half year, 1.62% in the last year, and 65.74% year-to-date.
On January 7, Sage Therapeutics issued a press release announcing positive top line results from its Phase 3 ROBIN trial evaluating SAGE-217 in postpartum depression indications. Thereafter, the company’s share price jumped 42.68% and closed at $139.13 on January 7.
Sage Therapeutics is currently enrolling patients in its Phase 3 MOUNTAIN study to evaluate SAGE-217 in MDD (major depressive disorder) indications. Top line results from this trial are expected in the fourth quarter of 2019 or the first quarter of 2020.
According to the company’s fourth-quarter earnings conference call, it’s also studying SAGE-217 in its RAINFOREST study for patients suffering from MDD and comorbid insomnia.
On March 19, Sage Therapeutics issued a press release announcing the FDA’s approval of its drug Zulresso in postpartum depression indications.